Article

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort study

2025-02-28

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) presents major therapeutic difficulties that need for creative solutions. Although their respective processes are different, CAR T-cell therapy and Blinatumomab have yet unknown relative efficacy. <bold>Objectives</bold> Guiding optimum treatment choice in high-risk DLBCL patients, this research intends...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 38783746-2246-56b2-bfb1-6aff9f85f1bf
DOI: 10.21203/rs.3.rs-6104849/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studyDOI 10.21203/rs.3.rs-6104849/v1Read

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in CanadaSemantic proximity Read

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialSemantic proximity Read

Double-Hit Large B Cell Lymphoma.Semantic proximity Read

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysisSemantic proximity Read

Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular PhenotypeSemantic proximity Read

Burkitt lymphoma: bridging the gap between advances in molecular biology and therapySemantic proximity Read

Classifying DLBCL Subtypes for Optimal Treatment.Semantic proximity Read

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Semantic proximity Read

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read